Current clinicopathological characterisation of adamantinoma - a review of the literature
DOI:
https://doi.org/10.12775/JEHS.2023.47.01.003Keywords
adamantinoma, other mesenchymal tumours of bone, differentiated adamantinoma, osteofibrous dysplasia-like adamantinoma, rare bone tumourAbstract
Introduction and purpose
Adamantinoma is an exceedingly rare, primary bone tumour, that in most cases affects the diaphysis of the long bones, especially the tibia. Histologically it is epithelial cells clusters surrounded by spindle-cell osteofibrous components. Adamantinoma has metastatic potential to the lungs and local lymph nodes. Both the rarity of the disease and its nonspecific symptoms complicate diagnosis and treatment. Reviewing the up-to-date data regarding adamantinoma was the purpose of the work.
State of knowledge
During the 5th edition of the World Health Organization (WHO) classification of bone tumours in 2020 adamantionoma was classified in the newly established bone tumour class of the other mesenchymal tumours of bone. What is more its name was specified to adamantionoma of the long bone. According to literature and newest classification adamantinoma is divided into 3 types; the most common classic adamantinoma as well as less frequent OFD-like adamantinoma (osteofibrous like adamantinoma) and dedifferentiated adamantinoma. Diagnosis is challenging due to the rarity of occurrence, insufficient knowledge and misinterpretation of imaging studies resulting in the diagnosis of adamantinoma as other bone and soft tissue tumours.
Conclusions
Confirmation of the immunohistochemical profile, as well as the genetic profile of adamantionoma, which are increasingly well-defined, is essential for diagnosis. Imaging studies still remain the first method used in the diagnostic process. MRI appears to be the most suitable method for the imaging diagnosis of adamantinoma, due to excellent imaging of the tumour extent, including its surrounding soft tissue involvement and possible metastases. As far as treatment is concerned, there are still no precise guidelines and the best option remains tumour resection with large margins
References
Altmannsberger M, Poppe H, Schauer A. An unusual case of adamantinoma of long bones. J Cancer Res Clin Oncol. 1982;104(3):315–20.
Deng Z, Gong L, Zhang Q, Hao L, Ding Y, Niu X. Outcome of osteofibrous dysplasia-like versus classic adamantinoma of long bones: A single-institution experience. J Orthop Surg Res. 2020;15(1):1–9.
Horvai A, Dashti NK, Rubin BP, Kilpatrick SE, Rudzinski ER, Lopez-Terrada D, et al. Genetic and molecular reappraisal of spindle cell adamantinoma of bone reveals a small subset of misclassified intraosseous synovial sarcoma. Mod Pathol [Internet]. 2019;32(2):231–41. Available from: http://dx.doi.org/10.1038/s41379-018-0115-6
Sahito B, Jatoi NN, Kumar D, Asad A, Hasan SS, Ali M. Understanding The Rare Bone Tumor “ADAMANTINOMA.” J Ayub Med Coll Abbottabad. 2021;33 1)(4):S835–40.
Varvarousis DN, Skandalakis GP, Barbouti A, Papathanakos G, Filis P, Tepelenis K, et al. Adamantinoma: An updated review. In Vivo (Brooklyn). 2021;35(6):3045–52.
Kashima TG, Dongre A, Flanagan AM, Hogendoorn PCW, Taylor R, Athanasou NA. Podoplanin expression in adamantinoma of long bones and osteofibrous dysplasia. Virchows Arch. 2011;459(1):41–6.
Ali NM, Niada S, Morris MR, Brini AT, Huen D, Sumathi V, et al. Comprehensive Molecular Characterization of Adamantinoma and OFD-like Adamantinoma Bone Tumors. Am J Surg Pathol. 2019;43(7):965–74.
Li JW, Miao L, Zhao ZG, Yang L, Shi Z, Li M. Osteofibrous dysplasia-like adamantinoma: A case report and literature review. Front Oncol. 2022;12(November):1–4.
Jain D, Jain VK, Vasishta RK, Ranjan P, Kumar Y. Adamantinoma: A clinicopathological review and update. Diagn Pathol. 2008;3(1).
Czerniak B, Rojas Corona R, Howard D. Morphologic Diversity of Long Bone Adamantinoma. Cancer. 1989;64:2319–34.
Zhang GH, Wu WJ, Huang MW. Recurrent adamantinoma of the mandible. Int J Oral Maxillofac Surg. 2021;50(8):1023–6.
Choi JH, Ro JY. The 2020 WHO Classification of Tumors of Bone: An Updated Review. Adv Anat Pathol. 2021;28(3):119–38.
Kahn LB. Adamantinoma, osteofibrous dysplasia and differentiated adamantinoma. Skeletal Radiol. 2003;32(5):245–58.
Shechter, Ari. Schwartz G. 乳鼠心肌提取 HHS Public Access. Physiol Behav. 2018;176(1):139–48.
Aytekin MN, Öztürk R, Amer K. Epidemiological Study of Adamantinoma from US Surveillance, Epidemiology, and End Results Program: III Retrospective Analysis. J Oncol. 2020;2020:4–11.
Varvarousis DN, Skandalakis GP, Barbouti A, Papathanakos G, Filis P, Tepelenis K, et al. Adamantinoma: An updated review. In Vivo (Brooklyn). 2021;35(6):3045–52.
Rekhi B, Sahay A, Puri A. Clinicopathologic Features of Two Rare Cases of Dedifferentiated Adamantinomas, Including Diagnostic Implications. Int J Surg Pathol. 2019;27(2):193–202.
Hazelbag HM, Laforga JB, Roels HJL, Hogendoorn PCW. Dedifferentiated Adamantinoma with Revertant Mesenchymal Phenotype. Am J Surg Pathol. 2003;27(12):1530–7.
Woude H Van Der, Hazelbag H, Bloem JL, Taminiau AHM, Hogendoorn PCW. MRI of Adamantinoma of Long. AJR Am J Roentgenol. 2004;183(December):1737–44.
Ulmar B, Delling G, Werner M, Huch K, Reichel H. Classical and atypical location of adamantinomas - Presentation of two cases. Onkologie. 2006;29(6):276–8.
Bhargava SK, Pal V, Gupta R. Adamantinoma of the tibia. A case report. Indian J Radiol. 1979;33(3):225–7.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Agata Węgrzyniak, Wojciech Wokurka, Dominik Drobek, Aleksandra Winiarz, Paula Szlendak, Katarzyna Toś, Kacper Wojtala, Michał Turek, Katarzyna Wąsala, Sylwia Grosman
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 508
Number of citations: 0
